---
title: "Edwards Lifesciences: Business Model"
description: "Edwards Lifesciences revenue by business segment from its fiscal 2025 Form 10-K, with each part's share, growth and profitability explained."
canonical: https://www.getswoopr.com/stocks/companies/edwards-lifesciences/business-model/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Edwards Lifesciences: Business Model & Revenue Engine

## Direct Answer

Edwards Lifesciences reports revenue across 4 business segments in its fiscal 2025 Form 10-K. United States is the largest, with $3.5 billion of revenue (58% of the total), followed by Europe at $1.5 billion (25%).

## How Does Edwards Lifesciences Make Money?

No single line supplies a majority of revenue: the largest, United States, is 58%, which spreads Edwards Lifesciences's exposure across several demand drivers. Between fiscal 2024 and 2025, Europe grew fastest (+14.8%) and Japan slowest (+4.4%), so the revenue mix tilts toward Europe while that gap lasts.

| Segment | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| United States | $3.5 billion | $3.2 billion | 58.4% | 10.5% |
| Europe | $1.5 billion | $1.3 billion | 25.0% | 14.8% |
| Rest of World | $652 million | $572 million | 10.8% | 14.0% |
| Japan | $355 million | $340 million | 5.8% | 4.4% |

![Bar chart of Edwards Lifesciences revenue by segment for fiscal 2025: United States 58.4%, Europe 25.0%, Rest of World 10.8%, Japan 5.8%.](https://www.getswoopr.com/images/charts/edwards-lifesciences-business-model-segment-mix.webp)
*Edwards Lifesciences revenue by segment as a share of total revenue, from the table above. The largest is highlighted. Select the chart to open it full size.*

## What Does Edwards Lifesciences Sell?

Edwards Lifesciences also breaks revenue down by product and service line, which shows what customers pay for rather than how management organizes the business.

| Product or service | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| Transcatheter Aortic Valve Replacement | $4.5 billion | $4.1 billion | 74.0% | 9.3% |
| Surgical Heart Valve Therapy | $1.0 billion | $981 million | 17.0% | 4.9% |
| Transcatheter Mitral and Tricuspid Therapies | $551 million | $352 million | 9.1% | 56.4% |

## What the Segment Figures Do Not Show

The rows above add up to 100% of Edwards Lifesciences's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.

## Where These Numbers Come From

Every figure on this page is a value Edwards Lifesciences reported in the segment note and revenue disclosures of its Form 10-K filed February 25, 2026 (accession 0001099800-26-000009), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.

Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.

## Frequently Asked Questions

### What are Edwards Lifesciences's business segments?

In its fiscal 2025 Form 10-K, Edwards Lifesciences reports revenue for United States, Europe, Rest of World and Japan.

### Which part of Edwards Lifesciences brings in the most revenue?

United States, with $3.5 billion of revenue in fiscal 2025, or 58% of the total.

### Where does Edwards Lifesciences report its segment results?

In the segment note to the financial statements in its Form 10-K, most recently filed February 25, 2026, alongside management's discussion of each segment's results.

## References

- [SEC EDGAR: Edwards Lifesciences Corp Form 10-K filed February 25, 2026](https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm)
- [SEC EDGAR: Edwards Lifesciences Corp annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1099800&type=10-K)
- [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces)
- [SEC: Financial Statement Data Sets](https://www.sec.gov/data-research/sec-markets-data/financial-statement-data-sets)

## Related Pages

- [Edwards Lifesciences company dossier](https://www.getswoopr.com/stocks/companies/edwards-lifesciences/)
- [Edwards Lifesciences financial metrics](https://www.getswoopr.com/stocks/companies/edwards-lifesciences/metrics/)
- [Edwards Lifesciences financial risk indicators](https://www.getswoopr.com/stocks/companies/edwards-lifesciences/risks/)
- [Edwards Lifesciences peer comparison](https://www.getswoopr.com/stocks/companies/edwards-lifesciences/competitors/)
- [Edwards Lifesciences business model and revenue mix](https://www.getswoopr.com/stocks/companies/edwards-lifesciences/business-model/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).